ArticleNature communications2026
An intelligent MRI-based all-in-one diagnostic strategy for axillary lymph node status in breast cancer.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An integrated diagnostic strategy of preoperative identification of sentinel lymph node (SLN) metastasis, SLN metastatic burden, and non-SLN (NSLN) metastasis in breast cancer remains to be developed to guide axillary surgery de-escalation. Here we develop a magnetic resonance imaging-based hierarchical multitask deep learning model, breast cancer axillary lymph node network (BCALN-Net) to predict SLN metastasis, SLN metastatic burden, and NSLN metastasis in 6,271 breast cancer patients. BCALN-Net achieves high performance in predicting SLN metastasis, SLN metastatic burden, and NSLN metastasis and exhibits robust performance across molecular subtypes, clinical tumor stages, clinical node stages, estrogen receptor statuses, human epidermal growth factor receptor 2 statuses, menopausal statuses, and SLN metastatic burdens. In pooled analysis of 4,081 patients, BCALN-Net also shows superior performance in predicting the omission of axillary invasive procedures and added value over clinical criteria. BCALN-Net holds the potential to provide an integrated diagnostic strategy of ALN status to help axillary surgery de-escalation in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.